STOCKHOLM – IRLAB Therapeutics AB, a Swedish biotech firm, is set to participate in the upcoming ABGSC Investor Days event where they will highlight their progress in developing treatments for Parkinson’s disease. The company’s presentations, led by CEO Gunnar Olsson and EVP Nicholas Waters (NYSE:), will take place on Wednesday at Hotel At Six in Stockholm, with a focus on their advanced clinical trials and preclinical entities derived from the research of Nobel Laureate Prof. Arvid Carlsson.
The company has scheduled its presentation for 13:00-13:30 UTC, which will also be available via live stream for wider accessibility. The discussion will center on IRLAB’s innovative therapies, including Mesdopetam (IRL790), which is gearing up for Phase III trials aimed at addressing levodopa-induced dyskinesias—a common side effect experienced by patients undergoing treatment for Parkinson’s disease.
Additionally, the presentation will cover Pirepemat (IRL752), currently in a Phase IIb trial focused on improving balance and reducing fall frequency among Parkinson’s patients. This is a significant concern as balance issues can lead to increased risk of injury for those suffering from the disease.
IRLAB’s research pipeline is driven by its proprietary ISP platform and includes three preclinical programs—IRL942, IRL757, and IRL1117—progressing towards Phase I studies. These programs further represent the company’s commitment to advancing the treatment options available for central nervous system disorders.
The upcoming event is an opportunity for investors and stakeholders to gain insight into IRLAB’s strategic initiatives and the potential impact of their Parkinson’s therapies. IRLAB Therapeutics is publicly traded on Nasdaq Stockholm under the ticker ‘IRLAB A’.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here